Global Hemophilia Treatment Market US$ 17 Billion by 2023

The global hemophilia treatment market to attain US$ 17 Billion by 2023, growing at a CAGR of 5.5% over the forecast period.

While less than 1 million people suffer from hemophilia A or B globally, they are among some of the most costly patients to treat because of frequent transfusions, costly medicines and often have a poor health prognosis, particularly in the absence of treatment. There are ~39,000 patients with haemophilia A and ~10,000 patients with haemophilia B across the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) plus the United States.

Visit the global hemophilia treatment market by indication (hemophilia A, hemophilia B, hemophilia with inhibitors, von Willebrand disease); by product class [recombinant coagulation factor (factor VIII, factor IX, hemophilia with inhibitors, von Willebrand disease), plasma-derived coagulation factor (factor VIII factor IX, hemophilia with inhibitors, von Willebrand disease)]; by treatment regime [prophylaxis (factor VIII, factor IX, inhibitors, von Willebrand disease), on-demand (factor VIII, factor IX, inhibitors, von Willebrand disease)]; by patient [adult hemophilia a, hemophilia b, hemophilia with inhibitors, von Willebrand disease), pediatric (hemophilia A, hemophilia B, hemophilia with inhibitors, von Willebrand disease)]; and by distribution channel (e-commerce, hospital pharmacies, retail pharmacies); by geography and forecast 2015-2023 at https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/

The global hemophilia treatment market report provides market size (Revenue USD Million 2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to 2023). The global hemophilia treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hemophilia drugs market report also provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis and tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global hemophilia treatment market and included in this report are Bayer AG, Biogen Idec, Biomarin, Biotest AG, CSL Behring, F. Hoffmann-La Roche Ltd., Grifols, Kedrion, Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., and Shire Plc (Baxter/Baxalta).

1. Indication
1.1. Hemophilia A
1.2. Hemophilia B
1.3. Hemophilia with Inhibitors
1.4. von Willebrand disease

2. Product Class
2.1. Recombinant Coagulation Factor
2.1.1. Factor VIII
2.1.2. Factor IX
2.1.3. Hemophilia with Inhibitors
2.1.4. von Willebrand disease
2.2. Plasma Derived Coagulation Factor
2.2.1. Factor VIII
2.2.2. Factor IX
2.2.3. Hemophilia with Inhibitors
2.2.4. von Willebrand disease

3. Treatment Regime
3.1. Prophylaxis
3.1.1. Factor VIII
3.1.2. Factor IX
3.1.3. Hemophilia with Inhibitors
3.1.4. von Willebrand disease
3.2. On-Demand
3.2.1. Factor VIII
3.2.2. Factor IX
3.2.3. Hemophilia with Inhibitors
3.2.4. von Willebrand disease

4. Patient
4.1. Adult
4.1.1. Hemophilia A
4.1.2. Hemophilia B
4.1.3. Hemophilia with Inhibitors
4.1.4. von Willebrand disease
4.2. Pediatric
4.2.1. Hemophilia A
4.2.2. Hemophilia B
4.2.3. Hemophilia with Inhibitors
4.2.4. von Willebrand disease

5. Distribution Channel
5.1. E-commerce
5.2. Hospital Pharmacies
5.3. Retail Pharmacies

6. Geography (Region, Country)
6.1. North America (U.S., Canada)
6.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
6.3. Latin America (Brazil, Mexico, Rest of LA)
6.4. Asia Pacific (Japan, China, India, Rest of APAC)
6.5. Rest of the World (Middle East & Africa)

7. Company Profiles
7.1. Bayer AG
7.2. Biogen Idec
7.3. Biomarin
7.4. Biotest AG
7.5. CSL Behring
7.6. F. Hoffmann-La Roche Ltd.
7.7. Grifols
7.8. Kedrion
7.9. Novo Nordisk A/S
7.10. Octapharma AG
7.11. Pfizer, Inc.
7.12. Shire Plc (Baxter/Baxalta)

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.